Legal & General Group Plc Sells 4,264 Shares of argenex SE $ARGX

Legal & General Group Plc trimmed its holdings in shares of argenex SE (NASDAQ:ARGX) by 2.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 144,355 shares of the company’s stock after selling 4,264 shares during the quarter. Legal & General Group Plc’s holdings in argenex were worth $121,395,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of argenex by 91.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,828 shares of the company’s stock valued at $6,511,000 after buying an additional 4,217 shares during the period. American Century Companies Inc. grew its stake in shares of argenex by 11.6% during the 3rd quarter. American Century Companies Inc. now owns 229,770 shares of the company’s stock worth $169,474,000 after acquiring an additional 23,864 shares during the period. Allianz Asset Management GmbH increased its holdings in argenex by 21.3% in the 3rd quarter. Allianz Asset Management GmbH now owns 3,671 shares of the company’s stock worth $2,708,000 after acquiring an additional 645 shares during the last quarter. US Bancorp DE increased its holdings in argenex by 37.2% in the 3rd quarter. US Bancorp DE now owns 7,073 shares of the company’s stock worth $5,217,000 after acquiring an additional 1,919 shares during the last quarter. Finally, Sands Capital Management LLC bought a new stake in argenex in the 3rd quarter valued at about $12,262,000. 60.32% of the stock is currently owned by institutional investors.

argenex Stock Up 2.2%

ARGX stock opened at $838.49 on Friday. The stock has a 50-day simple moving average of $776.28 and a two-hundred day simple moving average of $815.12. argenex SE has a twelve month low of $510.05 and a twelve month high of $934.62. The firm has a market capitalization of $52.15 billion, a PE ratio of 37.33, a PEG ratio of 1.30 and a beta of 0.46.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. The firm had revenue of $1.31 billion for the quarter. On average, equities research analysts anticipate that argenex SE will post 25.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ARGX shares. Wells Fargo & Company increased their target price on shares of argenex from $1,247.00 to $1,260.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Wedbush reissued an “outperform” rating and issued a $1,000.00 price target on shares of argenex in a research report on Monday, March 9th. Weiss Ratings restated a “hold (c)” rating on shares of argenex in a research note on Monday, April 20th. Citizens Jmp raised their price objective on shares of argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a report on Friday, February 27th. Finally, HC Wainwright lifted their price objective on shares of argenex from $915.00 to $940.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,017.78.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.